Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus.

Autor: Schnittman SR; Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Kolossváry M; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Beck-Engeser G; Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA., Fitch KV; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Ambayec GC; Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA., Nance RM; Department of Medicine, University of Washington, Seattle, Washington, USA., Zanni MV; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Diggs M; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Chan F; Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA., McCallum S; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Toribio M; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Bamford L; Division of Infectious Diseases and Global Public Health, University of California, San Diego, San Diego, California, USA., Fichtenbaum CJ; Division of Infectious Diseases, University of Cincinnati, Cincinnati, Ohio, USA., Eron JJ; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA., Jacobson JM; Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, USA., Mayer KH; Fenway Health and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA., Malvestutto C; Division of Infectious Diseases, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Bloomfield GS; Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA., Moore RD; Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Umbleja T; Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA., Saag MS; Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA., Aberg JA; Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Currier JS; Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA., Delaney JAC; Department of Epidemiology, University of Washington, Seattle, Washington, USA.; College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada., Martin JN; Department of Epidemiology and Biostatistics, University of California, San Francisco School of Medicine, San Francisco, California, USA., Lu MT; Cardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Douglas PS; Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Ribaudo HJ; Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA., Crane HM; Department of Medicine, University of Washington, Seattle, Washington, USA., Hunt PW; Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA., Grinspoon SK; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2023 Sep 08; Vol. 10 (10), pp. ofad467. Date of Electronic Publication: 2023 Sep 08 (Print Publication: 2023).
DOI: 10.1093/ofid/ofad467
Abstrakt: Plasma vascular endothelial growth factor (VEGF) coreceptor neuropilin-1 (NRP-1) had the largest association with coronary plaque in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) proteomics analysis. With little known about NRP-1 in people with human immunodeficiency virus (PWH), we explored its relation to other proteins in REPRIEVE and validated our findings through a Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) case-cohort study by assessing its relation to host factors and incident cardiovascular disease and cancer. Within REPRIEVE, NRP-1 was associated with proteins involved in angiogenesis, signal transduction, immunoregulation, and cell migration/adhesion. Within CNICS, NRP-1 was associated with key host factors, including older age and male sex. NRP-1 was associated with an increased hazard of multiple cancers but a decreased prostate cancer risk. Finally, NRP-1 was most strongly associated with mortality and type 2 myocardial infarction. These data suggest that NRP-1 is part of a clinically relevant immunoregulatory pathway related to multiple comorbidities in PWH. Clinical Trials Registration . NCT02344290.
Competing Interests: Potential conflicts of interest. S. R. S. reports grant support through his institution from NIH/NIAID. M. V. Z. reports grant support through her institution from NIH/NIAID and Gilead Sciences, relevant to the conduct of the study, and grants from NIH/NIAID and NIH/NHLBI, outside the submitted work. M. T. reports grant support from NIH/NHLBI, American Heart Association, and Robert Wood Johnson Foundation, outside the submitted work. C. J. F. reports grant support through his institution from Gilead Sciences, ViiV Healthcare, GSK, Janssen, AbbVie, Merck, Amgen, and Cytodyn, outside the submitted work. J. J. E. reports grant support through his institution from Gilead Sciences, ViiV Healthcare, and Janssen and personal fees from ViiV Healthcare, Merck, and Gilead Sciences, outside the submitted work. J. M. J. reports grant support through his institution from NIH/NIAID. K. H. M. reports unrestricted research grants to his institution from Gilead Sciences, Merck, and ViiV Healthcare and has served on scientific advisory boards for Gilead and Merck, outside the submitted work. C. M. reports institutional research support by Lilly and honoraria from ViiV Healthcare and Gilead Sciences for advisory board membership, outside the submitted work. R. D. M. reports grant support to his institution from NIH/NIAID and NIH/National Institute on Drug Abuse (NIDA) relevant to the conduct of the study. T. U. reports grant support from NIH/NHLBI and Kowa Pharmaceuticals during the conduct of the study and grants from NIH/NIAID and NIH/National Institute on Aging (NIA), outside the submitted work. M. S. S. reports grant support from NIH/NIAID relevant to the conduct of the study. J. A. A. reports institutional research support for clinical trials from Emergent Biosolutions, Frontier Technologies, Gilead Sciences, GlaxoSmithKline, Janssen, Macrogenics, Merck, Pfizer, Regeneron, and ViiV Healthcare; personal fees for advisory boards from GlaxoSmithKline and Merck; and data and safety monitoring board membership for Kintor Pharmaceuticals, outside the submitted work. J. S. C. reports consulting fees from Merck and Co and Resvirlogix. J. A. C. D. reports through to his institution from NIH/NHLBI, outside the submitted work. H. J. R. reports grants from NIH/NIAID and NIH/NHLBI during the conduct of the study, as well as grants from NIH/NIAID, NIH/NHLBI, NIH/National Institute of Diabetes and Digestive and Kidney Diseases, and NIH/NIA, outside the submitted work. H. M. C. reports grants from NIH/NHLBI during the conduct of this study; grants through her institution from NIH/NIDA, the Agency for Healthcare Research and Quality, and ViiV Healthcare; and advisory board membership for Gilead, outside the submitted work. P. W. H. reports grant support through his institution from Gilead Sciences; drug donation for an NIH-sponsored clinical trial he is leading from Merck; and personal fees from ViiV Healthcare, Gilead Sciences, and Merck. S. K. G. reports grant support through his institution from Kowa Pharmaceuticals America, Gilead Sciences, and ViiV Healthcare for the conduct of the study; and grants from Theratechnologies and Navidea, personal fees from Theratechnologies and ViiV, and service on the scientific advisory board of Marathon Asset Management, all outside the submitted work. All other authors report no potential conflicts.
(© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje